NAYA Biosciences supports executive order on fertility treatment access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Support for IVF Accessibility: NAYA Biosciences endorses the U.S. President's executive order aimed at reducing IVF costs and improving access to fertility services, emphasizing the financial burden many face due to high treatment expenses and lack of insurance coverage.
Innovative Solutions: The CEO of NAYA Biosciences highlights their FDA-cleared INVOcell device as a potential affordable alternative for fertility treatments, aligning with the government's efforts to make such services more accessible.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
